• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Regulatory T cell epitope content in human antibodies decreases during maturation

by Elena Iemma | Apr 21, 2025

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

by Elena Iemma | May 23, 2024

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

by Elena Iemma | May 23, 2024

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

by Elena Iemma | Sep 12, 2023

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

by Elena Iemma | May 1, 2023

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell-Engagers 
« Older Entries

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?
  • Tregs as Medicine: Tolerance and InTolerance Seminar
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline